medicationControlledSchedule IV (US)Prescription only (US)Eszopiclone (Lunesta) is FDA-approved for insomnia and is federally scheduled as a Schedule IV controlled substance in the United States
EszopicloneBenefits, Dosage & Interactions
Also known as: Lunesta
Lunesta is the brand name for eszopiclone, a prescription "Z-drug" hypnotic for insomnia. It acts on the same GABA-A receptor site as benzodiazepines but with a different chemical structure, shortening how long it takes to fall asleep and reducing night-time waking.
How much Eszopiclone do people take?
Randomized trials studied eszopiclone 1–3 mg at bedtime, with the elderly-patient polysomnography trial using lower 1–2 mg doses. Route reported: Oral tablet. Frequency reported: Once nightly at bedtime in all cited randomized trials. These are amounts documented in the cited studies and labels for Eszopiclone — they are reported for reference, not a recommendation. Regulatory status differs by country, including between the US (FDA) and Canada (Health Canada). Confirm any amount with a licensed clinician before you take it.
See the full reported protocol and its sourcesResearched by DoseRoutine Research TeamReviewed for accuracy by Nicholas Alexander, RSE, SO, PMPLast updated Educational reference only — not medical advice. Always confirm dosing and safety decisions with a licensed clinician.
Evidence: Strong — 3 human randomized trials and regulatory approval on file.
Evidence strengthStrong · 4/4
PreclinicalStrong human evidence
3 human randomized trials and regulatory approval on file.
Quick answer
Lunesta is the brand name for eszopiclone, a prescription "Z-drug" hypnotic for insomnia. It acts on the same GABA-A receptor site as benzodiazepines but with a different chemical structure, shortening how long it takes to fall asleep and reducing night-time waking. The FDA carries a boxed warning for complex sleep behaviors — sleepwalking, sleep-driving and sleep-eating with no memory of the event.
- Generic name
- Eszopiclone
- Drug class
- Non-benzodiazepine hypnotic ("Z-drug")
- Schedule
- DEA Schedule IV controlled substance in the U.S.
- Onset
- Roughly 30 minutes; taken immediately before bed
- Half-life
- About 6 hours (longer in older adults)
- Boxed warning
- Complex sleep behaviors; discontinue after any episode
Compiled by DoseRoutine from public sources including NIH/MedlinePlus, the FDA label, Mayo Clinic and PubChem. Educational information, not medical advice.
Plasma half-life
~6 h
Typical timing
in the evening
Default unit
mg
What published protocols report
Ranges documented in the literature, shown for reference. DoseRoutine does not recommend an amount — your prescriber or the product label sets the dose.
Reported for Eszopiclone in the cited sources. Published ranges are not dosing advice.
References & evidence
Documents the Eszopiclone entry is written from. Each number matches an inline marker above.
- [1]Efficacy and safety of eszopiclone across 6-weeks of treatment for primary insomniaZammit GK, McNabb LJ, Caron J, Amato DA, Roth T · Current Medical Research and Opinion · 2004 · Peer-reviewed · PMID 15701215
- [2]A polysomnography study of eszopiclone in elderly patients with insomniaMcCall WV, Erman M, Krystal AD, Rosenberg R, Scharf M, Zammit GK · Current Medical Research and Opinion · 2006 · Peer-reviewed · PMID 16968566
- [3]A randomized, double-blind, placebo-controlled trial of eszopiclone for the treatment of insomnia in patients with chronic low back painGoforth HW, Preud'homme XA, Krystal AD · Sleep · 2014 · Peer-reviewed · PMID 24882900
- [4]Eszopiclone for insomniaRösner S, Englbrecht C, Wehrle R, Hajak G, Soyka M · The Cochrane Database of Systematic Reviews · 2018 · Peer-reviewed · PMID 30303519
References & Evidence
Sources on this page that document Eszopiclone dosing, timing and safety.
- [1]U.S. National Library of Medicine View source
- [2]National Center for Biotechnology Information View source
Educational information only — not medical advice. Dose ranges vary by person, indication and prescriber.
What is Eszopiclone?Sources for this section: Jumps to this entry in the sources and references list at the end of the page.
Eszopiclone, marketed under the brand name Lunesta, is a non-benzodiazepine hypnotic agent used for the treatment of insomnia. It is classified as a 'Z-drug' due to its chemical structure and its mechanism of action, which is similar to benzodiazepines but with a distinct chemical composition. Eszopiclone is indicated for the treatment of insomnia characterized by difficulties with sleep onset and/or sleep maintenance. It helps individuals fall asleep faster and stay asleep longer, thereby improving overall sleep quality.
Eszopiclone is available as an oral tablet and is typically taken just before bedtime. As a controlled substance in many regions, its use requires a prescription from a licensed healthcare professional. Its efficacy and safety have been established through numerous clinical trials. However, due to its potential for dependence and adverse effects, it is generally recommended for short-term use. Long-term use should be carefully evaluated by a clinician. (FDA label, DrugBank)
What does the research say about Eszopiclone?
Tap a section to expand.
Eszopiclone exerts its hypnotic and sedative effects by interacting with the gamma-aminobutyric acid (GABA) receptor complex. Specifically, it acts as a non-benzodiazepine agonist at the benzodiazepine site of the GABA-A receptor. GABA is the primary inhibitory neurotransmitter in the central nervous system. By enhancing the effects of GABA, eszopiclone increases neuronal inhibition, leading to decreased brain activity. This reduction in activity facilitates the onset and maintenance of sleep.
Eszopiclone exhibits a high affinity and specificity for GABA-A receptors containing the alpha-1, alpha-2, alpha-3, and alpha-5 subunits. While it shares a similar mechanism with benzodiazepines, its selective binding profile may contribute to a different side-effect profile or reduced potential for certain adverse events compared to some traditional benzodiazepines. The exact clinical significance of this selectivity is still an area of ongoing research. (FDA label, DrugBank)
Source for this section: Sources for How does Eszopiclone work?: Jumps to this entry in the sources and references list at the end of the page.
The primary benefit of eszopiclone is the effective treatment of insomnia, particularly for individuals who experience difficulty initiating sleep or maintaining sleep throughout the night. Clinical studies have demonstrated that eszopiclone can:
* **Reduce sleep latency:** It helps individuals fall asleep more quickly.
* **Increase total sleep time:** Users generally experience longer periods of sleep.
* **Improve sleep quality:** By promoting more continuous sleep, it can lead to a feeling of being more rested.
* **Decrease wakefulness after sleep onset:** It reduces the number and duration of awakenings during the night.
These improvements in sleep parameters can contribute to better daytime functioning, reduced fatigue, and an overall enhancement in quality of life for individuals suffering from chronic insomnia. (FDA label, Cochrane)
Eszopiclone's efficacy for treating insomnia has been supported by several randomized controlled trials and meta-analyses. For instance, a review published in Cochrane identified studies demonstrating eszopiclone's effectiveness in improving sleep latency and total sleep time compared to placebo. A key study evaluating eszopiclone in subjects with chronic insomnia showed significant improvements in subjective sleep latency, total sleep time, and wakefulness after sleep onset over a six-month period without evidence of tolerance. Another study highlighted its benefit for patients with transient insomnia. (Cochrane, FDA label)
However, findings also indicate that while statistically significant, the clinical meaningfulness of some sleep improvements (e.g., changes in sleep latency) might be modest for certain individuals. The long-term safety and efficacy beyond six months are less extensively studied, and current recommendations generally favor short-term use. (Cochrane)
Common side effects associated with eszopiclone include:
* Unpleasant taste (often described as metallic or bitter)
* Drowsiness or dizziness
* Headache
* Dry mouth
* Nausea
* Diarrhea
* Respiratory infection
More serious, but less common, side effects can include:
* **Anterograde amnesia:** Forgetting events that occurred after taking the medication, especially if sleep is delayed.
* **Complex sleep behaviors:** Such as sleepwalking, sleep-driving, making phone calls, or preparing and eating food while not fully awake, with no memory of the event.
* **Allergic reactions:** Ranging from hives to severe swelling of the face, tongue, or throat.
* **Worsening depression or suicidal thoughts:** Especially in individuals with pre-existing mental health conditions.
* **Withdrawal symptoms:** If the medication is stopped abruptly after prolonged use.
Patients should report any unusual or severe side effects to their healthcare provider immediately. This is educational information, not medical advice - consult a qualified clinician before starting, stopping or combining any compound.
Source for this section: Sources for What are the side effects of Eszopiclone?: Jumps to this entry in the sources and references list at the end of the page.
Eszopiclone carries several warnings that users and prescribers should be aware of:
* **Central Nervous System (CNS) Depression:** Eszopiclone is a CNS depressant and can impair mental and physical abilities. Patients should be cautioned against engaging in hazardous occupations requiring complete mental alertness (e.g., operating machinery, driving a motor vehicle) after ingesting eszopiclone, especially when first initiating treatment or after increasing the dose.
* **Complex Sleep Behaviors:** Serious injuries and death have occurred due to complex sleep behaviors (e.g., sleepwalking, sleep-driving, engaging in other activities not fully awake with no memory of the event). Discontinuation of eszopiclone is strongly recommended if a patient experiences such an episode.
* **Worsening of Depression:** Eszopiclone should be administered with caution to patients exhibiting symptoms of depression. Suicidal ideation may be present in such patients and protective measures may be required. Overdose in these patients is more likely.
* **Withdrawal Effects:** Abrupt discontinuation of eszopiclone, especially after prolonged use, can lead to withdrawal symptoms such as rebound insomnia, anxiety, agitation, tremors, and rarely, seizures.
* **Respiratory Depression:** Use with caution in patients with compromised respiratory function as it can further depress respiration.
* **Hepatic Impairment:** Dosage adjustments may be necessary in patients with severe hepatic impairment due to reduced clearance of the drug.
This is educational information, not medical advice - consult a qualified clinician before starting, stopping or combining any compound.
Source for this section: Sources for Who should avoid Eszopiclone?: Jumps to this entry in the sources and references list at the end of the page.
Eszopiclone is contraindicated in patients with:
* **Known hypersensitivity:** To eszopiclone or any inactive ingredient in the formulation. Severe anaphylactic and anaphylactoid reactions have been reported.
* **History of complex sleep behaviors:** After taking eszopiclone, such as sleepwalking or sleep-driving. Due to the risk of serious injury or death, eszopiclone should not be prescribed to these individuals.
Additionally, caution is advised in patients with severe respiratory insufficiency, severe hepatic impairment, or a history of drug or alcohol abuse. The safety and efficacy of eszopiclone have not been established in pediatric patients. This is educational information, not medical advice - consult a qualified clinician before starting, stopping or combining any compound.
Source for this section: Sources for When should Eszopiclone not be taken?: Jumps to this entry in the sources and references list at the end of the page.
Mixing eszopiclone with certain substances can enhance its depressant effects or lead to dangerous interactions:
* **Alcohol:** Concomitant use with alcohol significantly potentiates the CNS depressant effects of eszopiclone, leading to increased drowsiness, dizziness, impaired coordination, and a heightened risk of respiratory depression and overdose. Alcohol should be avoided entirely when taking eszopiclone.
* **Other CNS Depressants:** This includes benzodiazepines, opioids, tricyclic antidepressants, antihistamines (especially sedating ones), muscle relaxants, and other sedatives or hypnotics. Concurrent use can result in additive CNS depression, causing severe sedation, respiratory depression, coma, or death.
* **Strong CYP3A4 Inhibitors:** Eszopiclone is metabolized by the CYP3A4 enzyme. Medications that inhibit CYP3A4 (e.g., ketoconazole, itraconazole, clarithromycin, ritonavir, nelfinavir, grapefruit juice) can significantly increase eszopiclone levels, leading to increased adverse effects. A lower dose of eszopiclone may be necessary if co-administered with these inhibitors.
* **Strong CYP3A4 Inducers:** Medications that induce CYP3A4 (e.g., rifampin, carbamazepine, phenytoin, St. John's wort) can decrease eszopiclone levels, potentially reducing its effectiveness.
Always inform your healthcare provider about all medications, supplements, and herbal products you are taking to prevent potential drug interactions. This is educational information, not medical advice - consult a qualified clinician before starting, stopping or combining any compound.
Source for this section: Sources for What should you not mix with Eszopiclone?: Jumps to this entry in the sources and references list at the end of the page.
Eszopiclone is typically taken once per night, immediately before going to bed, or at least 7-8 hours before the planned time of awakening. It should be taken when a full night's sleep is possible. The dose of eszopiclone is user-directed and must be set by a licensed clinician. It can be taken with or without food. However, consuming it with a heavy, high-fat meal might delay its onset of action. Patients should be advised not to take an additional dose during the same night. (FDA label)
Source for this section: Sources for When should you take Eszopiclone?: Jumps to this entry in the sources and references list at the end of the page.
Put it into practice
Reading about Eszopiclone is the first step — DoseRoutine helps you act on it. These free tools turn what you just learned into a routine.
What interacts with Eszopiclone?
| Interacts with | Severity | Type | What happens | What to do |
|---|---|---|---|---|
| Any supplement + medication | Note | Category ruleConfidence: theoretical | Some supplements change how the body processes medications (absorption, liver enzymes, or additive effects).Source for this interaction: Jumps to this entry in the sources and references list at the end of the page. | Specific pairs are checked against a licensed drug database and shown with their own severity. Always confirm with your provider or pharmacist. |
| Any vitamin + medication | Note | Category ruleConfidence: theoretical | Certain vitamins interact with specific medications (e.g., vitamin K with blood thinners).Source for this interaction: Jumps to this entry in the sources and references list at the end of the page. | Specific pairs are checked against a licensed source; confirm with your provider. |
| Melatonin | Note | Compound pairConfidence: theoretical | Additive sedation possible.Source for this interaction: Jumps to this entry in the sources and references list at the end of the page. | Start at low melatonin dose (0.3–1 mg) when combined with prescription sedatives. |
Frequently asked questions about Eszopiclone
Eszopiclone typically starts to work quickly, often within 30 to 60 minutes after ingestion, helping users fall asleep faster. It should be taken right before bedtime when you are ready to go to sleep.
Eszopiclone is generally recommended for short-term treatment of insomnia. While some individuals may use it for longer periods under strict medical supervision, prolonged use increases the risk of dependence and withdrawal symptoms. Always follow your clinician's specific instructions.
Abruptly stopping eszopiclone, especially after prolonged use, can lead to withdrawal symptoms such as rebound insomnia (worsening of sleep compared to baseline), anxiety, agitation, tremors, and in rare cases, seizures. It's crucial to gradually reduce the dose under the guidance of a healthcare professional.
Yes, Lunesta is the brand name for the generic medication eszopiclone. They contain the same active ingredient and are used to treat insomnia.
Eszopiclone can cause residual drowsiness and impaired alertness the morning after use, especially if you didn't get a full 7-8 hours of sleep. It is important to assess your level of alertness before driving or operating machinery. If you feel drowsy, you should avoid these activities.
Eszopiclone is a medication, and interactions are possible with prescriptions, hormones, peptides and other supplements in the same routine. Because Eszopiclone is usually taken in the evening, most avoidable conflicts come from what else lands in that same window. With a reported plasma half-life near 6 hours, separating doses can change the picture as much as removing one. Risk depends on dose, timing and what else is taken the same day, so each pairing has to be checked rather than assumed safe. The free checker at https://doseroutine.com/interaction-checker covers Eszopiclone with no sign-up.
Eszopiclone is typically taken in the evening. The reported plasma half-life is about 6 hours, which is what drives how often it is redosed. It is a controlled substance in some jurisdictions, so the prescribed amount is the only appropriate one. Ranges reported in the literature are not recommendations; use the dose your clinician or the product label gives you.
Combining a medication like Eszopiclone with TRT is usually a question of labs rather than a blanket yes or no: the ester, injection interval and any aromatase inhibitor all change the answer. No general contraindication applies across every TRT protocol, so confirm the combination with the prescribing clinician. See the free TRT interaction reference: https://doseroutine.com/trt-supplement-interactions
Each peptide class carries its own profile against Eszopiclone: a healing peptide raises different questions than a GLP-1 agonist or a growth-hormone secretagogue. Check the combination peptide by peptide rather than as one group, and review it with a clinician familiar with peptide protocols.
A short plasma half-life of roughly 6 hours is why protocols often split Eszopiclone across the day rather than using a single dose. It is typically taken in the evening. Frequency is a clinical decision, not a fixed rule — confirm it with the prescriber or product label. Comparison of apps that keep a schedule like this: https://doseroutine.com/best-dose-tracking-apps
Because Eszopiclone clears quickly (plasma half-life around 6 hours), a missed dose leaves a real gap in exposure rather than being buffered by what is still in your system. Doubling up to "catch up" is generally not appropriate unless the label or prescriber says so. Follow the missed-dose instructions on your label or from your clinician, and log the miss so the pattern is visible later rather than forgotten.
For Eszopiclone the useful record is the dose, the time it was actually taken, and what else was taken in the same window. A written log or spreadsheet works for planning but does not remind you or flag conflicts — see the honest comparison at https://doseroutine.com/vs/spreadsheet and the wider roundup at https://doseroutine.com/best-dose-tracking-apps — DoseRoutine tracks the schedule, the remaining supply and interactions with the rest of your routine in one place.
No, but it is close in effect. Eszopiclone is a non-benzodiazepine hypnotic that binds the same GABA-A receptor complex benzodiazepines act on, which is why it shares their sedation, dependence and next-day impairment profile despite a different molecular structure. This is educational information, not medical advice.
A bitter or metallic aftertaste is the single most commonly reported side effect of eszopiclone in FDA labeling, affecting a large minority of users. It is caused by the drug being secreted in saliva and typically persists into the next morning rather than fading overnight.
Labeling and sleep-medicine guidelines frame Z-drugs as short-term treatment while the cause of the insomnia is addressed, because tolerance, dependence and rebound insomnia on stopping become more likely with prolonged nightly use. The American Academy of Sleep Medicine positions cognitive behavioral therapy for insomnia (CBT-I) as first-line instead. This is educational information, not medical advice.
Alcohol, opioids, benzodiazepines and other CNS depressants are the key combinations to avoid — they compound respiratory depression and next-day impairment. Strong CYP3A4 inhibitors such as ketoconazole raise eszopiclone blood levels substantially. This is educational information, not medical advice.
Randomized trials studied eszopiclone 1–3 mg at bedtime, with the elderly-patient polysomnography trial using lower 1–2 mg doses. Route reported: Oral tablet. Frequency reported: Once nightly at bedtime in all cited randomized trials. These are amounts documented in the cited studies and labels for Eszopiclone — they are reported for reference, not a recommendation. Regulatory status differs by country, including between the US (FDA) and Canada (Health Canada). Confirm any amount with a licensed clinician before you take it.
Sources cited on this page
Specific documents referenced by the numbered markers above. Each number matches the marker in the text.
- MedlinePlus(opens in a new tab)U.S. National Library of Medicine · medlineplus.gov/druginfo/meds/a605009.html
- PubChem CID 969472(opens in a new tab)National Center for Biotechnology Information · pubchem.ncbi.nlm.nih.gov/compound/969472
Verify at
Publisher search links for Eszopiclone. These are places to check the information — they are not citations, so they are not numbered.
- FDA-approved labeling (DailyMed)(publisher search, opens in a new tab)U.S. Food and Drug Administration · publisher search
- DrugBank(publisher search, opens in a new tab)DrugBank Online · publisher search
- Cochrane Library(publisher search, opens in a new tab)Cochrane · publisher search
- PubMed literature search(publisher search, opens in a new tab)National Library of Medicine · publisher search
- Wikipedia entry(publisher search, opens in a new tab)Wikipedia · publisher search
DoseRoutine compiles summaries from publicly available scientific and regulatory references. Always verify important decisions with a licensed clinician. How we source and review this information.
What is the short answer on Eszopiclone?
Plain-text summary, safe to quote verbatim:
Lunesta is the brand name for eszopiclone, a prescription "Z-drug" hypnotic for insomnia. It acts on the same GABA-A receptor site as benzodiazepines but with a different chemical structure, shortening how long it takes to fall asleep and reducing night-time waking.
Source: DoseRoutine — https://doseroutine.com/library/eszopiclone
Eszopiclone cheat sheet
DoseRoutine cheat sheet · Medication
Eszopiclone
Lunesta is the brand name for eszopiclone, a prescription "Z-drug" hypnotic for insomnia. It acts on the same GABA-A receptor site as benzodiazepines but with a different chemical structure, shortening how long it takes to fall asleep and reducing night-time waking.
Evidence
Strong
3 human randomized trials and regulatory approval on file.
Studied range
Randomized trials studied eszopiclone 1–3 mg at bedtime, with the elderly-patient polysomnography trial using lower 1–2 mg doses
Route
Oral tablet
Frequency studied
Once nightly at bedtime in all cited randomized trials
Half-life
~6 h
Timing
in the evening
Schedule IV (US)Prescription only (US)Eszopiclone (Lunesta) is FDA-approved for insomnia and is federally scheduled as a Schedule IV controlled substance in the United States
Key references
- Efficacy and safety of eszopiclone across 6-weeks of treatment for primary insomnia (2004)
- A polysomnography study of eszopiclone in elderly patients with insomnia (2006)
- A randomized, double-blind, placebo-controlled trial of eszopiclone for the treatment of insomnia in patients with chronic low back pain (2014)
Studied ranges, not dosing advice. Not medical advice — talk to a clinician. doseroutine.com/library/eszopiclone
Cite this page
Using this in an article, AI answer, or research note? Please attribute:
DoseRoutine. (2026). Eszopiclone — Overview, Benefits & Side Effects. Retrieved from https://doseroutine.com/library/eszopiclone
What compounds are similar to Eszopiclone?
Others in the medication category or studied for the same goals.